LRRK2-Inhibitors-Modulators-MCE.docx 免費(fèi)下載
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、 HYPERLINK https:/www.MedChemE/Targets/LRRK2.html LRRK2Leucine-rich repeat kinase 2Leucine-rich repeat kinase 2 (LRRK2) is a ubiquitously expressed member of the ROCO protein family. LRRK2 is a complex,multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein
2、 interaction domains. LRRK2 isthe genetic cause of both familial and idiopathic Parkinsons disease (PD), and it is associated with neuronal death, vesicletrafficking, mitochondrial dysfunction, and inflammation.LRRK2 is a very large protein comprised of 2527 amino acids which has been determined to
3、contain multiple functional domains,including armadillo (ARM), ankyrin-repeats (ANK), leucine-rich repeats (LRR), Ras of complex proteins (ROC), C-terminal of Roc(COR), MAPK-like kinase, and WD40 motifs. Mutations in LRRK2 represent a significant component of both sporadic and familialPD. Pathogenic
4、 mutations cluster in the enzymatic domains of LRRK2, and kinase activity seems to correlate with cytotoxicity,suggesting the possibility of kinase-based therapeutic strategies for LRRK2-associated PD. The best-characterized mutation to date,G2019S, leads to increased kinase activity, and mutations
5、in the GTPase domain, such as R1441C and R1441G, have also beenreported to influence kinase activity.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/LRRK2.html LRRK2 HYPERLINK https:/www.MedChemE/Targets/LRRK2.html HYPERLINK https:/www.MedChemE/Targets/LRRK2.html Inhibitors HYPERLINK https:/www
6、.MedChemE/CZC-25146.html CZC-25146 HYPERLINK https:/www.MedChemE/CZC-25146.html HYPERLINK https:/www.MedChemE/czc-25146-hydrochloride.html CZC-25146 HYPERLINK https:/www.MedChemE/czc-25146-hydrochloride.html HYPERLINK https:/www.MedChemE/czc-25146-hydrochloride.html hydrochlorideCat. No.: HY-15800A
7、Cat. No.: HY-15800CZC-25146 is a potent, selective and metabolicallystable LRRK2 inhibitor with IC50 of 4.76 nM/6.87nM for wild type LRRK2 and G2019S LRRK2respectively.CZC-25146 Hcl is a potent, selective andmetabolically stable LRRK2 inhibitor with IC50 of4.76 nM/6.87 nM for wild type LRRK2 and G20
8、19SLRRK2 respectively.Purity: 98.85%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/CZC-54252.html CZC-54252 HYPERLINK https:/www.MedChemE/CZC-54252.html HYPERLINK https:
9、/www.MedChemE/czc-54252-hydrochloride.html CZC-54252 HYPERLINK https:/www.MedChemE/czc-54252-hydrochloride.html HYPERLINK https:/www.MedChemE/czc-54252-hydrochloride.html hydrochlorideCat. No.: HY-B0792 Cat. No.: HY-B0792ACZC-54252 is a potent and selective LRRK2inhibitor with IC s of 1.28 nM and 1.
10、85 nM for50wild-type and G2019S LRRK2, respectively.CZC-54252 attenuates G2019S LRRK2-induced humanneuronal injury with an EC of 1 nM. CZC-5425250has a neuroprotective activity.Purity: 99.18%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 10 mg, 50 mgCZC-54252 hydrochloride is a potent and s
11、electiveLRRK2 inhibitor with IC s of 1.28 nM and 1.85 nM50for wild-type and G2019S LRRK2, respectively.G2019S LRRK2-induced human neuronal injury isattenuated by CZC-54252 hydrochloride with anEC of 1 nM.50Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChem
12、E/eb-42486.html EB-42486 HYPERLINK https:/www.MedChemE/eb-42486.html HYPERLINK https:/www.MedChemE/GNE-7915.html GNE-7915Cat. No.: HY-142647 Cat. No.: HY-18163EB-42486 is a novel, potent, and highly selectiveG2019S-LRRK2 inhibitor (IC 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity:
13、99.79%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/gne-7915-tosylate.html GNE-7915 HYPERLINK https:/www.MedChemE/gne-7915-tosylate.html HYPERLINK https:/www.MedChemE/gne-7915-tosylate.html tosylate HYPERLINK https:/www.MedChe
14、mE/gne-7915-tosylate.html HYPERLINK https:/www.MedChemE/GNE-9605.html GNE-9605Cat. No.: HY-18163A Cat. No.: HY-12282GNE-7915 tosylate is a potent, selective andbrain-penetrant inhibitor of LRRK2 with an ICof 9 nM.50GNE-9605 is a highly potent, selective, andbrain-penetrant LRRK2 inhibitor with IC50
15、of 19nM. IC50 value: Target: LRRK2 GNE-9605 retainedexcellent predicted human metabolic stability whenassayed in human liver microsomes and hepatocytes.Purity: 99.62%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.72%Clinical Data: No Development R
16、eportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/GNE0877.html GNE0877 HYPERLINK https:/www.MedChemE/GNE0877.html HYPERLINK https:/www.MedChemE/GSK2578215A.html GSK2578215ACat. No.: HY-15796 Cat. No.: HY-13237GNE0877 is a highly potent, selective, andbrain-penetrant a
17、minopyrazole leucine-rich repeatkinase 2 (LRRK2) small molecule inhibitor with anIC50 of 3 nM.GSK2578215A is a potent and highly selectiveLRRK2 inhibitor, which exhibits IC s of around5010 nM against both wild-type LRRK2 and the G2019Smutant.Purity: 98.89%Clinical Data: No Development ReportedSize:
18、10 mM 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mgPurity: 99.79%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/HG-10-102-01.html HG-10-102-01 HYPERLINK https:/www.MedChemE/HG-10-102-0
19、1.html HYPERLINK https:/www.MedChemE/IKK-16.html IKK HYPERLINK https:/www.MedChemE/IKK-16.html HYPERLINK https:/www.MedChemE/IKK-16.html 16Cat. No.: HY-13488 Cat. No.: HY-13687HG-10-102-01 is a potent and selective inhibitorof wild-type LRRK2(IC50=23.3 nM) and the G2019Smutant(IC50=3.2 nM) IC50 Valu
20、e: 23.3 nM (WTLRRK2); 3.2 nM (LRRK2 G2019S) Target: LRRK2HG-10-102-01 maintains the ability to potentlyinhibit the biochemical activity of wild-typeIKK 16 is a selective IB kinase (IKK) inhibitorfor IKK2, IKK complex and IKK1 with IC s of 4050nM, 70 nM and 200 nM, respectively. IKK16 alsoinhibits le
21、ucine-rich repeat kinase-2 (LRRK2)with an IC of 50 nM.50Purity: 99.34%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 99.09%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html IKK
22、 HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html 16 HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/ikk-16-hydrochloride.html HY
23、PERLINK https:/www.MedChemE/JH-II-127.html JH-II-127Cat. No.: HY-13687A Cat. No.: HY-16936IKK 16 hydrochloride is a selective IB kinase(IKK) inhibitor for IKK2, IKK complex and IKK1 withIC s of 40 nM, 70 nM and 200 nM, respectively.50IKK16 also inhibits leucine-rich repeat kinase-2(LRRK2) with an IC
24、 of 50 nM.50JH-II-127 is a highly potent, selective, and brainpenetrant LRRK2 inhibitor, with IC50 of 6.6 nM,2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S,LRRK2-A2016T.Purity: 98.0%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mgPurity: 98.02%Clinical Data: No Development R
25、eportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/LRRK2_inhibitor_1.html LRRK2 HYPERLINK https:/www.MedChemE/LRRK2_inhibitor_1.html HYPERLINK https:/www.MedChemE/LRRK2_inhibitor_1.html inhibitor HYPERLINK https:/www.MedChemE/LRRK2_inhibitor_1.html HYPERLINK https:/www
26、.MedChemE/LRRK2_inhibitor_1.html 1 HYPERLINK https:/www.MedChemE/LRRK2_inhibitor_1.html HYPERLINK https:/www.MedChemE/LRRK2-IN-1.html LRRK2-IN-1Cat. No.: HY-111493 Cat. No.: HY-10875LRRK2 inhibitor 1 is a potent, selective and oralLRRK2 inhibitor with an pIC of 6.8.50LRRK2-IN-1 is a potent andselect
27、ive LRRK2 inhibitorwith IC of 6 nM and 13 nM for50LRRK2 (G2019S) and LRRK2 (WT), respectively.Purity: 99.72%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.19%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 10 mg, 50 mg, 100 mg, 500 mg HYPERLINK h
28、ttps:/www.MedChemE/lrrk2-in-2.html LRRK2-IN-2 HYPERLINK https:/www.MedChemE/lrrk2-in-2.html HYPERLINK https:/www.MedChemE/lrrk2-in-3.html LRRK2-IN-3Cat. No.: HY-145317 Cat. No.: HY-145318LRRK2-IN-2 (compoubd 22) is a potent, selective,orally active and brain-penetrant inhibitorLRRK2, with IC of 98%C
29、linical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/lrrk2-in-4.html LRRK2-IN-4 HYPERLINK https:/www.MedChemE/lrrk2-in-4.html HYPERLINK https:/www.MedChemE/MLi-2.html MLi-2Cat. No.: HY-144074 Cat. No.: HY
30、-100411LRRK2-IN-4 is a potent, selective, CNS-penetranand orally active leucine-rich repeat kinase 2(LRRK2) inhobitor with an IC of 2.6 nM.50LRRK2-IN-4 has the potential for the research ofParkinsons disease.MLi-2 is an orally active and highly selectiveLRRK2 inhibitor with an IC of 0.76 nM. MLi-250
31、has the potential for Parkinsons disease.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.74%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/PF-06447475.html PF-06447475 HYPERLINK https:/www.Med
32、ChemE/PF-06447475.html HYPERLINK https:/www.MedChemE/pf-06454589.html PF-06454589Cat. No.: HY-12477 Cat. No.: HY-112855PF-06447475 is a highly potent, selective andbrain penetrant LRRK2 inhibitor with an IC of 350nM.PF-06447475 is a highly potent, selective, brainpenetrant LRRK2 kinase inhibitor wit
33、h IC values50of 3 nM and 11 nM for WT LRRK and G2019S LRRK2,respectively. PF-06447475 can be used forparkinsons disease (PD) research.Purity: 99.88%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/pf-06456384.html PF-06456384 HYPERLINK https:/www.MedChemE/pf-06456384.html HYPERLINK https:/www.MedChemE/pf-06456384-trihydrochloride.html PF-06456384 HYPERLINK https:/www.MedChemE/pf-06456384-trihyd
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2026廣西欽州市市直衛(wèi)生健康系統(tǒng)欽聚英才招聘34人考試備考試題及答案解析
- 2026河南鄭州汽車工程職業(yè)學(xué)院招聘38人(含高層次人才崗)考試備考試題及答案解析
- 2026北京中國綠發(fā)部分二級(jí)戰(zhàn)新產(chǎn)業(yè)單位高管社會(huì)招聘5人考試備考題庫及答案解析
- 2025內(nèi)外貿(mào)一體化認(rèn)證服務(wù)指南-動(dòng)力電池產(chǎn)業(yè)
- 2026年包頭鋼鐵職業(yè)技術(shù)學(xué)院高職單招職業(yè)適應(yīng)性測試模擬試題帶答案解析
- 2026上海市臨床檢驗(yàn)中心招聘1人考試備考試題及答案解析
- 中鐵廣州局2026屆校園招聘考試參考試題及答案解析
- 2026年中國煙草總公司合肥設(shè)計(jì)院招聘7人考試備考試題及答案解析
- 2026年杭州西湖區(qū)青少年宮誠聘教師(非事業(yè))筆試參考題庫及答案解析
- 2026年衡水市第三中學(xué)招聘備考題庫參考答案詳解
- 內(nèi)河電動(dòng)船舶充換電模式的經(jīng)濟(jì)性與適用性分析
- 刮板撈渣機(jī)課件
- 《城市軌道交通全自動(dòng)運(yùn)行系統(tǒng)驗(yàn)收規(guī)范》
- 幼兒園3-6歲兒童學(xué)習(xí)與發(fā)展指南語言領(lǐng)域課件
- 透析液檢測不合格應(yīng)急預(yù)案
- 印刷機(jī)操作安全培訓(xùn)課件
- 醫(yī)療糾紛大數(shù)據(jù)及其預(yù)測模型-洞察及研究
- 2025《招投標(biāo)與合同管理》期末考試試卷(含答案)
- 商場員工安全培訓(xùn)課件
- 醫(yī)院信訪維穩(wěn)工作總結(jié)匯報(bào)
- 2025年中國便攜式制氧機(jī)市場調(diào)查研究報(bào)告
評(píng)論
0/150
提交評(píng)論